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Background and Objectives: Insomnia is a putative causal factor for persecutory thinking. Recent epide-
miological studies show a strong association of insomnia and paranoia. The clinical implication is that
reducing insomnia will reduce paranoid delusions. This study, evaluating for the ﬁrst time the treatment
of insomnia in individuals with persecutory delusions, provides a test of this hypothesis. It was predicted
that a brief cognitive behavioural intervention for insomnia (CBT-I) for individuals with persistent
persecutory delusions and sleep difﬁculties would not only reduce the insomnia but that it would also
reduce the paranoia.
Methods: Fifteen patients with persistent persecutory delusions and insomnia in the context of
a psychotic disorder were each individually given a standard-format, four-session CBT-I intervention.
Outcome assessments were conducted at pre-treatment, post-treatment and one-month follow-up.
Results: There were no missing data. Following the intervention, signiﬁcant reductions were found in
levels of insomnia and the persecutory delusions. The effect sizes were large, and the changes were
maintained at the follow-up. At least two-thirds of participants made substantial improvements in
insomnia and approximately half showed substantial reductions in the persecutory delusions. There
were also reductions in levels of anomalies of experience, anxiety and depression.
Limitations: The main limitations are the absence of a control group and unblinded assessments. A more
methodologically rigorous evaluation of this intervention is now warranted.
Conclusions: These preliminary ﬁndings suggest that CBT-I can be used to treat insomnia in individuals with
persecutory delusions and that, consistent with the hypothesised causal role, it also lessens the delusions.
 2011 Elsevier Ltd. Open access under CC BY license.1. Introduction
Treatments for psychosis are likely to be improved by targeting
single symptoms using theoretically-driven interventions (Foster,
Startup, Potts, & Freeman, 2010; Ross et al., in press; Trower et al.,
2004). Persecutory delusions are one of the key psychotic experi-
ences, for which improvements in both pharmacological and
psychological treatments are needed (see reviews by Garety,
Bentall, & Freeman, 2008; Bebbington, Pilling, & Whittington,
2008). In the current report we take a putative causal factor of
persecutory delusions identiﬁed from recent research and evaluate
the effects of an intervention designed to reduce it. Insomnia -
difﬁculties with getting and staying asleep - is common in people
with paranoia and is likely to exacerbate psychotic experiences. Freeman).
Y license.(Freeman, Brugha et al., 2010; Freeman, Pugh, Vorontsova, &
Southgate, 2009). Given that there are efﬁcacious cognitive
behavioural treatments (CBT) for insomnia these should be evalu-
ated in psychosis populations, and they may well have the signiﬁ-
cant added beneﬁt of reducing persecutory delusions. This is the
aim of the work described in this report.
It is well established that insomnia is a cause of anxiety,
depression and anomalies of experience (e.g. Breslau, Roth,
Rosenthal, & Andreski, 1996; Morphy, Dunn, Lewis, Boardman, &
Croft, 2007; Luby, Frohman, Grisell, Lenzo, & Gottlieb, 1960),
which are all factors that raise the risk of persecutory thinking
(Freeman, 2007). Four recent studies have evaluated the link
between insomnia and paranoia. In the ﬁrst study it was found in
a small group of patients with persecutory delusions in the context
of psychosis that 27% had severe clinical insomnia, 27% had clinical
insomnia of moderate severity, and 30% sub-threshold insomnia
(Freeman et al., 2009). In the same study, there was a strong and
signiﬁcant association of persecutory thinking and insomnia
Table 1
Description of the CBT intervention.
Session Number Components of Session Details of Session
Session 1 Psycho-education What are sleep problems?
How common are sleep
problems?
What are the effects of
sleep problems?
How much sleep do I need?
What causes/maintains sleep
problems?
Formulation What is stopping me sleep?
Formulation examining
thoughts, emotions, physiological
symptoms and behaviours
associated with insomnia.
Goal Setting Goal-setting
Motivation to change
Sleep Diary Sleep diary rationale and practice
Session 2 Sleep Hygiene Tackling sleep problems
Lifestyle factors that affect sleep
Bedroom conditions
Changes in lifestyle I can make
and sleep preparation
Stimulus Control Associating bed with sleep
Bedtime routine
Wind-down routine
Session 3 Relaxation
Overcoming sleeperelated worry
Techniques to combat
sleeperelated worries
Activity during the day
Giving up trying to sleep
(paradoxical intention)
Session 4 Sleep Review What have I learnt?
Revisit goals
Which techniques worked for you?
Which techniques didn’t
work for you?
Relapse Prevention What strategies can I use to help
improve my sleep in the future?
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lysed data from the 2000 British National Psychiatric Morbidity
survey, a representative general population sample of over eight
thousand people, and found that insomnia was associated with
a two to threefold increase in the risk of paranoid thinking
(Freeman, Brugha et al., 2010). This association was subsequently
closely replicated in an analysis of the 2007 Adult Psychiatric
Morbidity Survey of over seven thousand people (Freeman,
McManus et al., 2010). Stronger evidence has been obtained from
a longitudinal follow-up of 2382 people from the 2000 British
National Psychiatric Morbidity survey, in which it was shown that
symptoms of insomnia at the ﬁrst assessment increased both the
likelihood of the new development of paranoid thinking and of the
persistence of existing paranoid thinking over the next 18 months
(Freeman et al., submitted for publication). Insomnia may be
a causal factor in both the development and maintenance of
paranoid thinking, and it is likely that in some instances a vicious
cycle occurs, with paranoid fears, inactivity, and sleep difﬁculties
exacerbating each other. In sum, the link between insomnia and
paranoia is theoretically plausible and is supported by an emerging
empirical literature. The clear next step is to test the effects of
reductions of insomnia on paranoid thinking.
Studies of insomnia show that it is associated with a negative
impact on individuals’ quality of life, health, relationships, ability to
perform at work and enjoyment of leisure activities (Smith, Huang,
& Manber, 2005). Chronic insomnia is often poorly managed and
treatment of chronic insomnia with pharmacotherapy remains
controversial because of issues of tolerance and dependency (Espie
et al., 2006; Morin et al., 1999; NICE 2004). In insomnia linked with
schizophrenia, treatment often involves antipsychotics and seda-
tive hypnotics which are only partially effective in the long term,
and are often associated with a daytime “hangover” effect, which
can contribute to poor global functioning (Kantrowitz, Citrome, &
Javitt, 2009). However, a large body of research, outside of
psychosis groups, has found that non-pharmacological cognitive
behavioural interventions (CBT-I) are highly effective (Espie et al.,
2006; Jacobs, Pace-Schott, Stickgold, & Otto, 2004; Morin et al.,
1999; Smith et al., 2005).
The present investigation aimed to provide an initial evaluation
of CBT-I intervention for people with persistent persecutory delu-
sions and co-morbid chronic insomnia. The main prediction was
that the insomnia intervention would lead to a reduction in both
insomnia and the delusions. The secondary prediction was that the
insomnia intervention would also reduce anxiety, depression and
anomalies of experience, which are potential mediators of the
relationship between insomnia and paranoia. The study provides
the ﬁrst direct evaluation of the effects of an insomnia intervention
for individuals with persecutory delusions and was therefore an
uncontrolled pilot study of potential efﬁcacy. We targeted patients
with delusions that had not responded to current treatments (i.e.
a persistent symptom group) in order to strengthen claims for the
effects of the intervention.
2. Method
The study hypotheses were tested in a pilot study using an open
uncontrolled trial methodology based on Harvey, Sharpley, Ree,
Stinson, and Clark (2007). Ethical approval for this study was
obtained from an NHS research ethics committee.
2.1. Participants
15 patients with persecutory delusions and insomnia partici-
pated. Criteria for inclusion in the trial were: primary diagnosis of
schizophrenia, psychotic disorder, psychosis, schizoaffectivedisorder or delusional disorder, as indicated by clinical case notes;
current experience of persecutory delusions as deﬁned by Freeman
and Garety (2000); persecutory delusions that had persisted,
despite treatment, for six months or longer; sleep difﬁculties
lasting for one month or longer; medication stable for at least one
month prior to taking part in the study; and aged between 18 and
65. Exclusion criteria were: unable to give informed consent; not
wanting help for sleep problems; currently involved in any other
cognitive behaviour therapy; and a primary diagnosis of drug or
alcohol dependence. Participants were recruited from outpatient
services.
2.2. Intervention
All participants were offered a four-session individual CBT-I
intervention (see Table 1). Each session lasted approximately 1 h.
The aimwas to deliver themweekly, though for some participants it
took eight weeks to complete four sessions. The main techniques,
standard for CBT sleep interventions, were taken from four main
sources: Espie (2006); Freeman and Freeman (2010); Harvey et al.,
(2007); Meir and Kryger (2004). Initially the sessions focussed
upon psycho-education about sleep difﬁculties, assessment of the
triggering and maintenance of sleep difﬁculties, and goal-setting.
Based upon the assessment, the active therapeutic techniques that
were used included sleep hygiene, stimulus control therapy (e.g.
setting appropriate and regular sleep times, not doing anything else
in the bed or bedroom apart from sleeping, not staying in bed if not
able to sleep for longer than 20e30 min, stopping daytime naps),
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unhelpful beliefs and attitudes about sleep, attentional bias,
monitoring, and safety behaviours. The intervention was deliber-
ately simpliﬁed, with the principal therapeutic technique being
stimulus control i.e. learning to associate bed with sleep. Partici-
pants were also given written information as part of the interven-
tion in the form of a newly-devised handbook to read between
sessions and on completion of the intervention. Therapy was
carried out by EM, supervised by DF, but adherence and compe-
tence was not formally assessed. The persecutory delusions were
not discussed in the sessions.2.3. Addendum to design
A baseline assessment had not been included in the original trial
design in order not to deter potential participants from taking part
in this initial evaluation. However after eight participants had been
through the intervention indicating positive outcomes, we
enhanced the design for the remaining seven patients with the
addition of a baseline measure one or two weeks prior to the pre-
treatment measure. The baseline measure included the same set of
outcome measures outlined below, so that the stability of the
participants’ symptoms could be assessed. Ethical approval was
obtained for this addendum to the design.2.4. Outcome measures
2.4.1. Insomnia Severity Index (ISI; Bastien, Vallieres, & Morin,
2001)
The ISI includes seven self-rated items evaluating the perceived
severity of insomnia on a ﬁve-point scale ranging from 0 (not at all)
to 4 (very much), according to the perceived degree of severity. The
total score is obtained by summing the seven items, for a possible
total score ranging from 0 to 28. A higher score indicates a greater
insomnia severity. The ISI indicates sleep difﬁculties involving both
day and night functioning and covers DSM-IV insomnia criteria
(American Psychiatric Association, 1994). Scoring guidelines are as
follows: 0e7, absence of clinically signiﬁcant insomnia; 8e14, sub-
threshold insomnia; 15e21, moderate clinical insomnia; and
22e28, severe clinical insomnia. The ISI was found to have
adequate internal consistency and is a reliable self-report measure
to evaluate perceived sleep difﬁculties (Bastien et al., 2001).
2.4.2. Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds,
Monk, Berman, & Kupferet, 1988)
The PSQI is a self-rated questionnaire which assesses sleep
quality and disturbances (Buysse et al., 1988). Nineteen individual
items generate seven “component” scores: subjective sleep quality,
sleep latency, sleep duration, habitual sleep efﬁciency, sleep
disturbances, use of sleeping medication, and daytime dysfunction.
Each item is rated on a scale from 0 (no difﬁculty) to 3 (severe
difﬁculty). The seven component scores are combined to produce
a global score (range of 0e21). A PSQI global score>5 is considered
to be suggestive of signiﬁcant sleep disturbance. Psychometric
properties of the PSQI were assessed over an l8-month period with
“good” sleepers (healthy subjects, n ¼ 52) and “poor” sleepers
(depressed patients, n ¼ 54; sleep-disorder patients, n ¼ 62)
(Buysse et al., 1988). The scale has been found to a high degree of
internal consistency between the seven component scores and
good test-retest reliability (Buysse et al., 1988). Regarding validity,
the PSQI was shown to provide a standardised, quantitative
measure of sleep quality that quickly identiﬁes good and poor
sleepers, and compares favourably with the “gold standard” of
clinical and laboratory diagnosis (Buysse et al., 1988).2.4.3. Green et al Paranoid Thought Scales (G-PTS; Green et al.,
2008)
The ‘Paranoid Thought Scales’ assess ideas of persecution and
reference over the past month. The measure includes two 16-item
scales, one assessing ideas of reference (Part A) (e.g. ‘I spent time
thinking about friends gossiping about me’ ‘People have been
checking up onme.’) and the other ideas of persecution (Part B) (e.g.
‘Certain individuals have had it in forme.’ ‘Iwas convinced therewas
a conspiracy aboutme’). Each item is rated on aﬁve-point scale from
1 (not at all) to 5 (totally). Scores on each subscale can range from 16
to 80. Higher scores represent a greater degree of ideas of reference
and persecution. Good internal consistency and validity has been
established for both scales and their dimensions (Green et al., 2008).
2.4.4. Psychotic Symptoms Rating Scale: Delusions Subscale
(PSYRATS; Haddock, McCarron, Tarrier, & Faragher, 1999)
The PSYRATS delusions sub scale is a six-item scale which
assesses the preoccupation, distress, duration, conviction, intensity
of distress and disruption associated with the delusion. Each item is
rated on a ﬁve-point ordinal scale from 0e4. The scale is used by
a clinician in the format of a structured interview and is designed to
rate the participant’s experiences over the last week. An exception
to this is item three (conviction) which is rated according to the
participant’s belief at the time of interview. The PSYRATS has found
to have sound psychometric properties (Drake, Haddock, Tarrier,
Bentall, & Lewis, 2007; Haddock et al., 1999).
2.4.5. Cardiff Anomalous Perception scale (CAPS; Bell, Halligan, &
Ellis, 2006)
The CAPS consists of 32 self-report items designed to assess
perceptual anomalies such as changes in levels of sensory intensity,
distortion of the external world, sensory ﬂooding and hallucina-
tions. Participants were asked to rate each item using a no (0)/yes
(1) format. A higher score indicates a higher number of perceptual
anomalies, scores range from 0 (low) to 32 (high). The internal
reliability of the CAPS is good, with a Cronbach’s alpha coefﬁcient of
.87 (Bell et al., 2006). Test-retest reliability has also been found to
be acceptable (Bell et al., 2006).
2.4.6. Depression Anxiety Stress Scales (DASS; Lovibond & Lovibond,
1995)
The DASS is a set of three self-report sub-scales designed to
measure the negative emotional states of depression, anxiety and
stress over the past week. For this study only the depression and
anxiety sub-scales were used. Each item is rated on a four-point
ordinal scale from 0e3. Scores range from 0 (low) to 42 (high) on
each 14 item subscale. In a clinical sample of 437 the internal
consistency (i.e. Cronbach’s alpha) of both the anxiety and
depression scale was high, .96 for the depression scale and .89 for
the anxiety scale (Brown, Chorpita, Korotitsch, & Barlow, 1997).
Temporal stability was also demonstrated in non-signiﬁcant test-
retest scores over a two-week time period (Brown et al., 1997).
2.5. Statistical analysis
All analyses were conducted using SPSS Version 15.0 (SPSS,
2007). Changes in each of the outcome measures across time
(pre-treatment, post-treatment, one-month follow-up) were
assessed using repeated measures analysis of variance (ANOVA).
Where the repeated analysis indicated signiﬁcant changes, differ-
ences between pre-treatment, post-treatment and one-month
follow-up were then investigated using pairwise comparisons.
Treatment effect sizes were calculated using Cohen’s d statistic
(Cohen, 1988): d ¼ Minitial Mpost=SDpooled. Reliable and clini-
cally-signiﬁcant change was reported for the measures used to test
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delusions. Clinically signiﬁcant change was deﬁned, using stringent
criteria, as pre-to post-intervention change of at least two standard
deviations from the original mean (Jacobsen & Truax, 1991), but we
also examined symptom reduction by 25% and 50%. Reliable change
was measured using the Reliable Change Index (RCI) which was
calculated using the formula: RCI ¼ ðX2 X1Þ=Sdiff ; Sdiff ¼
ﬃﬃﬃ
2
p

SEðsquaredÞ; SE ¼ SDpre
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 r
p
(Jacobsen & Truax, 1991). For the
design addendum it was hypothesised that there would not be
a signiﬁcant difference between baseline and pre-treatment on the
outcome measures. Statistical analysis to test this hypothesis for
this addendum involved administering paired t-tests to compare
baseline with pre-treatment scores. A power calculation was
carried out prior to the start of the trial. The aimwas to have at least
80% power to detect an effect size of .96 for a reduction in insomnia
(see the meta-analysis of Smith et al., 2005) using a single group
t-test with a .05 two-sided signiﬁcance level (Howell, 2007). This
would need a sample size of 11 participants. We aimed to recruit 15
patients, to allow for loss of data at follow-up.
3. Results
There were no missing data in the current investigation. All 15
participants completed the pre-treatment, post-treatment and
follow-up assessments (see Fig. 1 for ﬂowchart of participants
through the trial). Following an addendum to the study design,
seven participants completed an additional baseline measure.
3.1. Demographic and clinical characteristics of participants
The demographic details of the participants are summarised in
Table 2. It can be seen that this was a relatively older sample,Individuals referred (n = 25) 
Informed consent obtained (n = 17)  
Insomnia assessed 
Persecutory delusions 
assessed 
Significant sleep difficulties not 
present or not wanting 
psychological treatment for sleep 
difficulties = excluded (n = 0)
Persecutory delusions not present = 
excluded (n = 2) 
Four session CBT-I intervention 
(n = 15) 
Post-treatment measures 
 (assessment 2)  
(n ==15) 
One-month follow-up after the 
end of intervention 
(assessment 3)  
(n = 15) 
Remaining pre-treatment 
measures (assessment 1)  
(n =15)
Fig. 1. Flowchart of participants progress though the phases of the trial.consistent with the criterion of persistent delusions. Typical of this
population, most were single and living alone, however there were
more women than would normally be expected. Participants who
took part in the trial had a case note diagnosis of schizophrenia
(n ¼ 10), ‘psychotic disorder’ (n ¼ 2), delusional disorder (n ¼ 1),
and ‘psychosis’ (n ¼ 1). Symptom scores can be seen in Table 2. All
participants in the study fell within the moderate or severe clinical
insomnia range on the ISI and in the signiﬁcant sleep disturbance
range on the PSQI. Scores on the G-PTS and PSYRATS indicated that
the group had high levels of conviction in the persecutory belief,
and delusions that were distressing and preoccupying.
3.2. Overview of results
Themean scores of the outcomemeasures at each time point are
displayed in Table 3. It can be seen that there were signiﬁcant and
large reductions over time on all the measures.
3.3. Changes in insomnia
3.3.1. Insomnia Severity Index (ISI)
Pairwise comparisons indicated that pre-treatment ISI was
signiﬁcantly different to post-treatment ISI with amean decrease of
11.8 (p < .001; d ¼ 2.64) and follow-up ISI with a mean decrease of
10.73 (p < .001, d ¼ 2.63). Cohen’s d shows that the effect sizes are
large. Posttreatment ISI was not signiﬁcantly different to follow-up
ISI (p ¼ .20) (see Table 4). Calculation of clinical and reliable change
revealed that at post-treatment, 14 participants showed reliable
change and 10 made clinically-signiﬁcant change. At post-treat-
ment, nine participants had reduced ISI scores by 50%, and 14 had
reduced scores by 25%.
3.3.2. Pittsburgh Sleep Quality Index (PSQI)
Pairwise comparisons indicated that pre-treatment PSQI was
signiﬁcantly different to post-treatment PSQI with a mean decrease
of 8.67 (p < .001, d ¼ 2.31) and follow-up PSQI with a mean
decrease of 8.33 (p< .001, d¼ 2.39). Cohen’s d shows that the effect
sizes are large. Post-treatment PSQI was not signiﬁcantly differentTable 2
Demographic data.
All Participants
(N ¼ 15)
Gender
Female 9 (60%)
Male 6 (40%)
Mean age in years (SD) 45.47 (11.28)
Minimum 20
Maximum 64
Ethnicity
White 7 (46.7%)
Black Caribbean 1 (6.7%)
Black African 2 (13.3%)
Black Other 3 (20%)
Other 2 (13.3%)
Education
GCSE 8 (53.3%)
AS/A-Level 2 (13.3%)
Diploma/foundation degree 1 (6.7%)
Degree 3 (20%)
Post-graduate Diploma 1 (6.7%)
Marital Status
Single 11 (73.3%)
Divorced/separated 4 (26.7%)
Cohabiting
No 15 (100%)
Yes 0 (0%)
Table 3
Means and standard deviations (in parentheses) for main outcome measures.
Preetreatment
mean score
(SD)
Poste
treatment
mean score
(SD)
One-month
follow-up
mean score
(SD)
F p-value
Primary measures
Insomnia Severity
Index
20.93 9.13 10.20 53.87 <.001
(3.45) (5.30) (4.63)
Pittsburgh Sleep
Quality Index (PSQI)
15.60 6.93 7.27 52.20 <.001
(2.95) (4.42) (3.94)
PSQI Sleep duration 2.33 (1.05) .73 (1.10) .60 (.99) 26.48 <.001
PSQI Sleep latency 2.73 (.80) 1.40 (1.24) 1.73 (1.10) 11.97 <.001
Green Paranoid
Thoughts Scale: A
46.93 35.20 34.93 11.27 <.001
(13.27) (16.89) (15.60)
Green Paranoid
Thoughts Scale: B
58.27 39.60 38.93 16.11 .001
(15.93) (18.80) (20.80)
Psychotic Symptom
Rating Scale
18.33 15.07 14.00 17.21 <.001
(2.72) (3.06) (4.11)
Secondary measures
Cardiff Anomolous
Perceptions Scale
18.07 13.20 13.60 5.63 .018
(10.69) (9.68) (9.24)
DASS: Anxiety Scale 21.80 11.73 13.47 13.13 <.001
(9.05) (9.65) (10.53)
DASS: Depression
Scale
23.13 12.87 16.07 6.35 .008
(15.41) (14.37) (15.88)
Table 5
Pairwise comparisons for pre, post and follow-up G-PTS: A; G-PTS: B; PSYRATS
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reliable change revealed that at post-treatment, 14 participants
showed reliable change and 12 made clinically-signiﬁcant change.
At post-treatment, nine participants had reduced PSQI scores by
50%, and 13 had reduced scores by 25%.
3.4. Changes in persecutory delusions
3.4.1. Green Paranoid Thought Scales: Part A: ideas of reference (G-
PTS: A; Green et al., 2008; range 16e80)
Pairwise comparisons indicated that pre-treatment G-PTS: A
was signiﬁcantly different to post-treatment G-PTS: A with a mean
decrease of 11.73 (p ¼ .001, d ¼ .77) and follow-up G-PTS: A with
a mean decease of 12.00 (p ¼ .003, d ¼ .83). Cohen’s d shows that
the effect sizes are large. Post-treatment G-PTS: A was not signiﬁ-
cantly different to follow-up G-PTS: A (p ¼ .92) (see Table 5).
Calculation of clinical and reliable change revealed that at post-
treatment, eight participants showed reliable change and none
made clinically-signiﬁcant change. At post-treatment, two partici-
pants had reduced G-PTS: A scores by 50%, and seven had reduced
scores by 25%.
3.4.2. Green et al Paranoid Thought Scales: Part B: ideas of
persecution (G-PTS: B)
Pairwise comparisons indicated that pre-treatment G-PTS: B
was signiﬁcantly different to post-treatment G-PTS: B with a mean
decrease of 18.67 (p ¼ .001, d ¼ 1.07) and follow-up G-PTS: B with
a mean decrease of 19.33 (p ¼ .001, d ¼ 1.04). Cohen’s d shows that
the effect sizes are large. Post G-PTS: B was not signiﬁcantlyTable 4
Pairwise comparisons for pre, post and follow-up ISI and PSQI scores.
Measure Mean
Difference
Std.
Error
Sig. 95% CI
ISI Scores Pre vs. Post 11.80 1.57 <.001 8.43e15.17
Pre vs. Follow-up 10.73 1.29 <.001 7.97e13.50
Post vs. Follow-up 1.07 .78 .20 2.75e.61
PSQI Scores Pre vs. Post 8.67 1.17 <.001 6.17e11.17
Pre vs. Follow-up 8.33 1.05 <.001 6.07e10.59
Post vs. Follow-up .33 .60 .55 1.51e.85different to follow-up G-PTS: B (p¼ .71) (see Table 5). Calculation of
clinical and reliable change revealed that at post-treatment, seven
participants showed reliable change and ﬁve made clinically-
signiﬁcant change. At post-treatment, ﬁve participants had reduced
G-PTS: B scores by 50%, and eight had reduced scores by 25%.
3.4.3. Psychotic symptoms rating scale: delusions subscale
(PSYRATS)
Pairwise comparisons indicated that pre-treatment PSYRATS
was signiﬁcantly different to post-treatment PSYRATS with a mean
decrease of 3.27 (p < .001, d ¼ 1.13) and follow-up PSYRATS with
a mean decrease of 4.33 (p < .001, d ¼ 1.24). Cohen’s d shows that
the effect sizes are large. Post-treatment PSYRATS was not signiﬁ-
cantly different to follow-up PSYRATS (p ¼ .25) (see Table 5).
Calculation of clinical and reliable change revealed that at post-
treatment, 10 participants showed reliable change and two made
clinically-signiﬁcant change. At post-treatment, no participants had
reduced PSRATS scores by 50%, and four had reduced scores by 25%.
Though signiﬁcantly underpowered to examine this issue,
changes in persecutory thinking were associated with changes in
sleep. GPTS-Part A change (Pre-therapy e Post-therapy) was
correlated with ISI change (Pre-therapy e Post-therapy), r ¼ .71,
p ¼ .003, and PSQI change (Pre-therapy e Post-therapy), r ¼ .46,
p ¼ .085. Similarly, GPTS-Part B change was associated with ISI
change, r ¼ .69, p ¼ .005, and PSQI change, r ¼ .41, p ¼ .129.3.5. Changes in anomalous experience, anxiety and depression
3.5.1. Cardiff Anomalous Perception scale (CAPS)
Pairwise comparisons indicated that pre-treatment CAPS was
signiﬁcantly different to post-treatment CAPS with a mean differ-
ence of 4.87 (p ¼ .019, d ¼ .48) and follow-up CAPS with a mean
difference of 4.47 (p ¼ .03, d ¼ .45). Post-treatment CAPS was not
signiﬁcantly different to follow-up CAPS (see Table 6). Cohen’s
d shows that the effect sizes are medium.
3.5.2. Depression anxiety stress scales: anxiety sub-scale (DASS: A)
Pairwise comparisons indicated that pre-treatment DASS: Awas
signiﬁcantly different to post-treatment DASS: A with a mean
decrease of 10.07 (p ¼ .001, d ¼ 1.08) and follow-up DASS: A with
a mean decrease of 8.33 (p ¼ .001, d ¼ .85). Post-treatment DASS:
A was not signiﬁcantly increase to follow-up DASS: A (see Table 6).
Cohen’s d shows that the effect sizes are large.
3.5.3. Depression anxiety stress scales: depression sub-scale (DASS:D)
Pairwise comparisons indicated that pre-treatment DASS:D was
signiﬁcantly different to post-treatment DASS: D with a mean
decrease of 10.27 (p ¼ .006, d ¼ .69) and follow-up DASS: D with
a mean decrease of 7.07 (p ¼ .05, d ¼ .45). Post-treatment DASS: Dscores.
Measure Mean
Difference
Std.
Error
Sig. 95% CI
G-PTS: A Scores Pre vs. Post 11.73 2.65 .001 6.06e17.41
Pre vs. Follow-up 12.00 3.29 .003 4.95e19.05
Post vs. Follow-up .27 2.68 .92 5.48e6.01
G-PTS: B Scores Pre vs. Post 18.67 4.28 .001 9.48e27.85
Pre vs. Follow-up 19.33 4.84 .001 8.95e29.72
Post vs. Follow-up .67 1.76 .71 3.11e4.44
PSYRATS scores Pre vs. Post 3.27 .60 <.001 1.99e4.55
Pre vs. Follow-up 4.33 .80 <.001 2.61e6.06
Post vs. Follow-up 1.07 .88 .25 .82e2.96
Table 6
Pairwise comparisons for pre, post and follow-up CAPS; DASS Anxiety; DASS
Depression scores.
Measure Mean
Difference
Std. Error Sig. 95% CI
CAPS Scores Pre vs. Post 4.87 1.84 .019 .92e8.81
Pre vs.
Follow-up
4.47 1.85 .03 .49e8.44
Post vs.
Follow-up
.40 .98 .69 2.5e1.70
DASS: Anxiety
Scores
Pre vs. Post 10.07 2.39 .001 4.93e15.20
Pre vs.
Follow-up
8.33 1.91 .001 4.24e12.43
Post vs.
Follow-up
1.73 1.97 .39 5.95e2.48
DASS: Depression
scores
Pre vs. Post 10.27 3.18 .006 3.46e17.08
Pre vs.
Follow-up
7.07 3.29 .05 .02e14.12
Post vs.
Follow-up
3.20 2.28 .18 8.08e1.68
Table 7
Means, standard deviations (in parentheses) and t values for all outcome measures.
Baseline Pre-treatment t (df ¼ 6) p-value
Insomnia Severity
Index
20.43 (4.47) 21.57 (3.46) .738, .489
Pittsburgh Sleep
Quality Index
16.29 (2.36) 17.00 (2.00) .645, .542
Green Paranoid
Thoughts Scale: A
52.43 (16.56) 47.71 (13.03) 1.795, .123
Green Paranoid
Thoughts Scale: B
53.00 (17.46) 53.71 (19.28) .308, .768
Psychotic Symptom
Rating Scale
19.00 (2.58) 19.29 (2.63) 1.55, .172
Cardiff Anomolous
Perceptions Scale
15.57 (8.56) 15.71 (9.20) .121, .908
DASS: Anxiety
Scale
21.14 (11.89) 21.29 (11.06) .040, .969
DASS: Depression
Scale
27.86 (15.13) 28.86 (17.75) .512, .627
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Table 6). Cohen’s d shows that the effect sizes are medium.
3.6. Addendum to design
Baseline data were available for seven participants. It can be
seen in Table 7 that there were no changes in the outcome
measures prior to the intervention.
3.7. Medication
Fourteen participants were taking neuroleptic medication and
one participant was not. All those taking medication were on
atypical antipsychotics. Converting the antipsychotic doses to
chlorpromazine equivalents, six were on low doses of medication
(200 mg chlorpromazine or less), seven were on medium doses
(201e400 mg chlorpromazine), and one was on a high dose
(>400 mg chlorpromazine). Seven participants were also taking
anti-depressant medications, and one of these individuals was also
prescribed an anxiolytic. Of those taking medication, 13 partici-
pants had no change during the period of the trial, consistent with
the short length of duration of the trial and the already lengthy
treatment history. One participant had a change from 300 mg of
Quetiapine to 350 mg of Quetiapine between the post-treatment
and follow-up assessment.
3.8. Adverse events
No participant had to be withdrawn from the trial, and there
were no adverse events. One participant who received CBT-I was
admitted as an inpatient to a psychiatric hospital following suicidal
thoughts, but the participant and care team did not believe that this
was linked to the insomnia intervention and the suicidal ideation
had been present prior to entering the trial.
4. Discussion
We have reported the ﬁrst test of an insomnia intervention for
individuals with persistent persecutory delusions. The results are
very promising. Across all the different outcome measures the
results were consistent. There were substantial and signiﬁcant
reductions in insomnia and persecutory delusions. The sleep inter-
vention, which did not discuss the delusions, nevertheless
decreased paranoia, which is consistent with a causal role forinsomnia in the maintenance of psychotic symptoms. This was
a group of patients with long-term and signiﬁcant difﬁculties, who
would be considered as difﬁcult to treat, but who took very well to
a targeted intervention that focussed on a key concern. We recom-
mend more systematic assessment and treatment of sleep difﬁcul-
ties in patients with persecutory delusions. However there is a clear
caveat. This was a pilot study, with no control group and unblinded
assessments. A randomised controlled trial is now required.
All the participants completed the four session intervention. The
results clearly indicate that following the CBT-I intervention, the
participants reported signiﬁcant reductions in insomnia as
measured by both the Insomnia Severity Index (ISI) and the Pitts-
burgh Sleep Quality Index (PSQI). The effect size of the reductions
was large. More than two-thirds of participants showed both reli-
able and clinically-signiﬁcant change following the intervention.
Around half of participants made a 50% improvement and the
majority of participants made a 25% improvement on the measures
of insomnia. The effect sizes found in the current study are
comparablewith those found inmore rigorous clinical trials of non-
pharmacological treatments for insomnia (Morin et al., 1999), and
those found in other trials of CBT-I for co-morbid insomnia (Smith
et al., 2005). The beneﬁts of the intervention were maintained at
the one-month follow-up, which suggests at least a short-term
durability of the treatment on insomnia, which is again in keeping
with previous treatment studies of non-pharmacological treat-
ments of insomnia (Morin et al., 1999).
Despite the persecutory delusions not being a topic of discus-
sion in the intervention sessions, an improvement in sleep resulted
in a lessening of paranoid experiences. The results revealed that
following the CBT-I intervention there was a signiﬁcant reduction
in paranoia as measured by the Green et al Paranoid Thoughts Scale
(G-PTS) Part A (ideas of reference), G-PTS Part B (ideas of perse-
cution) and the Psychotic Symptoms Rating Scale (PSYRATS) at
post-treatment and one-month follow-up. The effect sizes were
large. Approximately one half of the participants showed
substantial reductions in paranoia on the basis of reliable and
clinically-signiﬁcant change. A small number of participants
improved by 50% and almost half of the participants made a 25%
improvement on measures of paranoid thinking. These ﬁndings are
consistent with a recent trial of the treatment of insomnia with
sodium salt or y-hydroxybutyric acid (SXB) in eight patients with
insomnia linked to schizophrenia (Kantrowitz et al., 2009).
Our introduction of a small baseline period into the study sup-
ported the idea that the participant group had persistent symptoms
and were not on a path of natural recovery, though this can only be
truly tested with a trial design that includes a control group.
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with reductions in levels of anomalies of experience, anxiety and
depression. The effect sizes for these reductions were moderate to
large, and are similar to those from previous research into CBT-I
treatment for insomnia co-morbid with other psychiatric condi-
tions (e.g. Smith et al., 2005). Our interest in these variables was
due to their being plausible routes that insomnia may contribute to
the occurrence of paranoid thinking. In previous cross-sectional
research there were indications that affective disturbance mediates
the relationship between insomnia and paranoia (Freeman et al.,
2009; Freeman, Brugha et al., 2010). In essence, reductions in
anxiety, depression, and anomalies of experience are likely to lead
to reductions in persecutory delusions (Freeman, Freeman, &
Garety, 2008; Foster et al., 2010).
We have highlighted basic elements of the design of this study
that limit the strength of conclusions that can be made at this stage
of development of the intervention. We also note that there was
only a single therapist, who also carried out the assessments,
though these measures were self-report as well as interviewer
rated. There was no assessment of therapist adherence or compe-
tence. However the simpliﬁed intervention we have devised will
have the advantage of being easily administered by other thera-
pists. The intervention does not rely on complex formulations or
difﬁcult therapeutic manoeuvres. A further weakness is the
multiple statistical testing with a relatively small sample size,
though conﬁdence is gained by all the measures showing similar
changes. Given that there is a substantial evidence base for cogni-
tive behavioural insomnia interventions, we recommend their use
for patients with psychosis reporting such difﬁculties. Our results
do not indicate that their effects will be any different for patients
with psychosis. Indeed, they hold the intriguing promise of
improving psychotic symptoms such as persecutory delusions.
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